A Broad Pipeline Approaching the Clinic
Using a delivery-centric approach to unlock the power of genetic medicines across many disease areas.
| Program | Discovery Lead Optimization IND Enabling Clinical Development | |
|---|---|---|
| Targeted LNPs | SIGMA-109 Targeted In Vivo CAR-T for Autoimmune Disease | mid IND Enabling phase |
| SIGMA-109 is a targeted in vivo CAR-T therapy designed to treat multiple B cell-mediated autoimmune diseases. | ||
| Next Gen Targeted LNP Programs | Discovery phase | |
| Antibody-Oligo Conjugates | Cardiac Targeted AOC | Lead Optimization Phase |
| Other Muscle Targeted AOC | Discovery phase | |
| Protein Nano-Particles | CNS Targeted PNP | Discovery phase |
Targeted LNPs
SIGMA-109: Targeted In Vivo CAR-T for Autoimmune Disease
SIGMA-109 is a targeted in vivo CAR-T therapy designed to treat multiple B cell-mediated autoimmune diseases.
Discovery
Lead Optimization
IND Enabling
Clinical Development
Next Gen Targeted LNP Programs
Discovery
Lead Optimization
IND Enabling
Clinical Development
Antibody-Oligo Conjugates
Cardiac Targeted AOC
Discovery
Lead Optimization
IND Enabling
Clinical Development
Other Muscle Targeted AOC
Discovery
Lead Optimization
IND Enabling
Clinical Development
Protein Nano-Particles
CNS Targeted PNP
Discovery
Lead Optimization
IND Enabling
Clinical Development